年龄、合并症与治疗特征对晚期高级别上皮性卵巢癌老年女性生存的影响
该回顾性研究纳入351例接受肿瘤细胞减灭术的晚期上皮性卵巢癌患者,其中100例(28.5%)≥70岁。老年组CIRS-G评分更高、辅助化疗完成率更低、腹腔内治疗更少、临床试验参与更少、铂敏感性和BRCA突变率更低,且满意减瘤率更低,PFS和OS更差;多因素分析显示较好OS与较年轻、接受腹腔内治疗、完成辅助化疗和铂敏感相关。
要点
- ≥70岁患者CIRS-G评分更高(5.9 vs 4.3),但合并症与治疗特征关联不强。
- 老年组满意减瘤率更低(75% vs 86.9%),尽管手术复杂度相似。
- 多因素分析中较好OS与<70岁、腹腔内治疗、完成辅助化疗及铂敏感相关。
核心结论
- 老年晚期上皮性卵巢癌患者预后更差,合并症的影响可能小于肿瘤生物学。
研究设计与样本
- 回顾性 chart review,纳入351例接受肿瘤细胞减灭术的患者,其中100例(28.5%)≥70岁。
主要发现
- ≥70岁组CIRS-G评分显著更高(5.9 vs 4.3;p=0.0001)。
- ≥70岁组辅助化疗完成率更低(24% vs 15.1%;p=0.049)。
- ≥70岁组腹腔内治疗更少(18.2% vs 35.5%;p=0.002)。
- ≥70岁组临床试验参与更少(16% vs 26.3%;p=0.040)。
- ≥70岁组铂敏感性更低(60% vs 73.7%;p=0.012)且BRCA突变缺失(0% vs 12%;p=0.0006)。
关键数值与推荐
- 多因素分析中较好OS与<70岁、任何腹腔内治疗、完成辅助化疗及铂敏感相关。
临床怎么用
- 对老年晚期上皮性卵巢癌患者应关注治疗完成度和腹腔内治疗机会,而非仅关注合并症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Older women have a worse prognosis with advanced epithelial ovarian cancer (EOC) and comorbidities likely contribute to poor outcomes. We sought to identify comorbid conditions and treatment-related factors in older women. METHODS: A retrospective chart review identified 351 patients who underwent cytoreductive surgery (CRS). 100/351 (28.5%) were ≥ 70 years old. Demographic and clinicopathologic information was collected. Crude progression-free (PFS) and overall survival (OS) estimates were calculated using Kaplan-Meier method. Cox proportional hazards regression model was used to estimate hazard ratios and adjustments for confounders. RESULTS: Study subjects ≥70 years old had significantly: higher Cumulative Illness Rating Scale-Geriatric (CIRS-G) score (5.9 vs 4.3; p = 0.0001), less completion of adjuvant chemotherapy (24% vs 15.1%; p = 0.049), less intraperitoneal (IP) therapy (18.2% vs 35.5%; p = 0.002), less clinical trial participation (16% vs 26.3%; p = 0.040), decreased platinum sensitivity (60% vs 73.7%; p = 0.012) and lacked BRCA mutations (0% vs 12%; p = 0.0006). They were less likely to have optimal CRS (75% vs 86.9%; p = 0.007) with same surgical complexity (p = 0.89). Patients ≥70 had significantly worse PFS and OS. In a multivariate analysis, better OS was associated with younger age (<70 years old), any IP therapy, completion of adjuvant chemotherapy, and platinum sensitivity. CONCLUSION: The older cohort had worse CIRS-G scores (5.9 vs 4.3; p = 0.0001), but no strong associations between comorbidities and treatment characteristics, but less optimal CRS rates (75% vs 86.9%; p = 0.007) with similar surgical complexity and less platinum sensitivity. Our results show comorbid conditions in older patients with advanced EOC may have less impact than tumor biology.
引用
- Mallen A, Todd S, Robertson SE, et al. Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer. Gynecol Oncol. 2021. PMID: 33812698. doi:10.1016/j.ygyno.2021.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。